HCP Live April 15, 2024
Although the intervention did not reduce risk of CKD progression versus standard care, it addressed barriers to care and increased patients’ exposure to ACEi/ARBs.
Findings from a pragmatic, cluster-randomized clinical trial are highlighting the potential of a multifaceted electronic health record and population health management strategy for addressing barriers to the implementation of evidence-based chronic kidney disease (CKD) care.1
Results from Kidney Coordinated Health Management Partnership (Kidney CHAMP) were published in JAMA Internal Medicine and showed that although the intervention did not reduce patients’ risk of CKD progression compared with usual care, it did increase exposure to angiotensin-converting enzyme inhibitors (ACEi)/angiotensin 2 receptor blockers (ARB) over a median follow-up of 17 months.1
“Despite the null result, we found that the...
Today's Sponsors
Today's Sponsor